Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust NYSE Arca Biotechnology UCITS ETF 20.02.2026 FBTU.LN IE00BL0L0H60 500,002.00 USD 12,767,106.51 25.534  ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Veris Residential, Inc. (NYSE: VRE) to an investor consortium led by Affinius Capital in partnership with Vista Hill Partners for $19.00 per share. Halper Sadeh encourages Veris shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation...

NEW YORK--(BUSINESS WIRE)--CI&T (NYSE: CINT, “Company”), a global partner in tech-integrated business solutions, announces that it will report its fourth quarter and full-year 2025 financial results after the market closes on March 11, 2026. Following the earnings release, CI&T's senior management team will host a video conference call to discuss the financial and operating results on the same day, March 11, at 4:30 PM Eastern Time / 5:30 PM BRT. The video conference call can be accesse...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Capital Strength UCITS ETF 20.02.2026 FTCS. IE00BL0L0D23 275,002.00 USD 9,362,025.01 34.043  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Value Line Dividend Index UCITS ETF 20.02.2026 FVD. IE00BKVKW020 250,002.00 USD 7,520,942.34 30.084  ...

ROME & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets,...

ROMA, ITALIA e CAMBRIDGE, MASSACHUSETTS--(BUSINESS WIRE)--Angelini Pharma, azienda farmaceutica parte del Gruppo Angelini Industries e Quiver Bioscience (“Quiver”), azienda specializzata in tecnologie per la scoperta e lo sviluppo di terapie innovative per il trattamento dei disturbi del sistema nervoso centrale (CNS), hanno annunciato oggi la sigla di collaborazione per la ricerca, lo sviluppo e la commercializzazione di nuove terapie per le epilessie genetiche. La collaborazione integra le co...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Capital Strength ESG Leaders UCITS ETF 20.02.2026 FCSG IE00BKPSPT20 1,400,002.00 USD 62,333,148.82 44.524  ...

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2025....

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 20.02.2026 FXGB LN IE00BD5HBR05 37,992.00 GBP 760,111.37 27.011  ...